Profil
Michael Pehl is Chief Executive Officer & Director at ADCendo ApS since 2021.
Formerly, Mr. Pehl was President, Chief Executive Officer & Director at Immunomedics, Inc. from 2017 to 2019, Chief Executive Officer at AvenCell Europe GmbH, and President-Global Hematology/Oncology at Celgene Corp.
from 2006 to 2017.
Mr. Pehl completed undergraduate education at Ludwig-Maximilians-Universität München.
Aktive Positionen von Michael Pehl
| Unternehmen | Position | Beginn |
|---|---|---|
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Vorstandsvorsitzender | 07.07.2021 |
Ehemalige bekannte Positionen von Michael Pehl
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOMEDICS, INC. | Vorstandsvorsitzender | 23.02.2019 |
| CELGENE | Corporate Officer/Principal | 21.08.2017 |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Vorstandsvorsitzender | - |
Ausbildung von Michael Pehl
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
















